KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas
08 Março 2024 - 8:30AM
Business Wire
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of oral, small molecule protease inhibitors,
today announced the acceptance of multiple abstracts at the 2024
HAEi Regional Conference meeting taking place in Panama City,
Panama from March 15-17. KalVista is a Silver-level sponsor of the
meeting. The presentations are:
- Relationship Between Time to On-demand Treatment and
Quality of Life During Hereditary Angioedema Attacks: Sandra
Christiansen, Timothy Craig, Maeve O’Connor, Cristine Radojicic,
Julie Ulloa, Sherry Danese, Vibha Desai, Tomas Andriotti, Paul
Audhya, Paula Busse. Results shared as an oral presentation as
part of Abstract Oral Presentations: Session 1 on Saturday, March
16 at 9:15 am EST in the Magnolia Room
- Anxiety Associated with On-Demand Treatment for Hereditary
Angioedema (HAE) Attacks: James Wedner, Cristine Radojicic,
Julie Ulloa, Sherry Danese, Vibha Desai, Paul Audhya, Sandra
Christiansen. Results shared as an oral poster presentation
and Q&A
- Delayed On-Demand Treatment of Hereditary Angioedema
Attacks: Patient Perceptions and Associated Barriers: Sandra
Christiansen, Maeve O’Connor, Julie
Ulloa, Sherry Danese, Vibha Desai, Paul Audhya, Paula Busse.
Results shared as an oral poster presentation and Q&A
- Characteristics of Hereditary Angioedema Attacks Among
Long-Term Prophylaxis Users: Bob Geng, Vibha Desai, Julie
Ulloa, Sherry Danese, Paul Audhya, Timothy Craig, Maeve O’Connor (presenter-only). Results shared as
an oral poster presentation and Q&A
- Treatment Patterns of Patients Requiring Redosing of an
On-demand Treatment After the Return of an HAE Attack:
Constance Katelaris, Michael Manning,
Sally van Kooten, Neil Malloy, Markus Heckmann, Julie Ulloa,
William Lumry
- Anxiety Associated with Refilling On-demand Therapy for HAE
Attacks Contributes to Treatment Delay and Non-Treatment:
Daniel F. Soteres, Anete S. Grumach,
Sally van Kooten, Neil Malloy, Markus Heckmann, Julie Ulloa, Autumn
Burnette
- Characterizing the Negative Impact of Delayed On-Demand
Treatment of HAE Attacks: Princess Ogbogu, Hilary Longhurst,
Sally van Kooten, Neil Malloy, Markus Heckmann, Julie Ulloa,
Ricardo Zwiener
All poster presentations will take place on Friday, March 15
starting at 7:20 p.m. EST in the Vetiver Room.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company
focused on the discovery, development, and commercialization of
oral, small molecule protease inhibitors for diseases with
significant unmet need. KalVista disclosed positive phase 3 data
for the KONFIDENT trial for its oral, on-demand therapy
sebetralstat in February 2024. The Company anticipates submitting a
new drug application to the U.S. FDA for sebetralstat in the first
half of 2024 and expects to file for approval in Europe and Japan
later in 2024. In addition, KalVista’s oral Factor XIIa inhibitor
program represents a new generation of therapies that may further
improve the treatment for people living with HAE and other
diseases.
For more information about KalVista, please visit
www.kalvista.com.
Forward-Looking Statements
This press release contains "forward-looking" statements within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: "anticipate,"
"intend," "plan," "goal," "seek," "believe," "project," "estimate,"
"expect," "strategy," "future," "likely," "may," "should," "will"
and similar references to future periods. These statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from what we expect. Examples of
forward-looking statements include, among others, timing or
outcomes of communications with the FDA, our expectations about
safety and efficacy of our product candidates and timing of
clinical trials and their results, our ability to obtain regulatory
approvals for sebetralstat and other candidates in development, the
success of any efforts to commercialize sebetralstat, the ability
of sebetralstat and other candidates in development to treat HAE or
other diseases, and the future progress and potential success of
our oral Factor XIIa program. Further information on potential risk
factors that could affect our business and financial results are
detailed in our filings with the Securities and Exchange
Commission, including in our annual report on Form 10-K for the
year ended April 30, 2023, our quarterly reports on Form 10-Q, and
our other reports that we may make from time to time with the
Securities and Exchange Commission. We undertake no obligation to
publicly update any forward-looking statement, whether written or
oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240308093167/en/
KalVista Pharmaceuticals, Inc. Jarrod Aldom Vice
President, Corporate Communications (201) 705-0254
jarrod.aldom@kalvista.com
Ryan Baker Head, Investor Relations (617) 771-5001
KalVista Pharmaceuticals (NASDAQ:KALV)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
KalVista Pharmaceuticals (NASDAQ:KALV)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024